Parkinson’s
Disease
Meet Hybridopa™
Our drug-software combination product in development that pairs immediate release carbidopa levodopa with a therapeutic protocol designed to improve signs and symptoms of Parkinson’s disease.
New to Hybridopa™? Join our community to follow the research as it develops.
Clinical Milestone:
Phase 3 Ready
Following a Phase 2 trial with promising results, we are launching our Phase 3 trial soon.
Approval
The "Levodopa Ceiling"
Over 10 million people worldwide are living with Parkinson’s Disease (PD), and nearly 90,000 people are newly diagnosed in the US with PD each year. It is a complicated neurodegenerative disease, and patients show a broad and diverse range of symptoms as the disease progresses.
Levodopa remains the gold standard for symptom management. As the disease progresses, patients face "wearing off" effects, freezing of gait, and speech deterioration that the drug alone cannot address.
Active Neural Reinforcement via Digital Interactions
Hybridopa™ is designed to enhance the impact of Levodopa and help retrain the brain.
Hybridopa™ combines immediate-release levodopa/carbidopa with an investigational therapeutic protocol delivered through a mobile application. TIt is designed to be adaptive and respond to patient performance, behavior, and clinical status with the goal of enhancing both motor and non-motor outcomes in Parkinson’s disease.
01 The Drug
Delivers necessary dopamine replacement.
02 The Digital Layer
A personalized, AI-driven protocol delivered via app to target the "Behavioral-Digital Pathway."
The Outcome
By synchronizing drug delivery with digital interventions we aim to maximize the functional benefit of every dose.
Primary Hybridopa Targets
Improve Brain Plasticity
Strengthening connectivity within and between neural networks impacted by PD.
Rebalance Emotion & Cognition
Psychological interventions designed to help address stress, anxious and depressive feelings, while building resilience.
Gamification & Reward Systems
Techniques to maintain reward system health and reinforce positive neuro-immunological responses.
Reduce Systemic & Neuro-inflammation
Modulating the HPA axis and sympathetic nervous system to lower pro-inflammatory cytokines.
Clinically Validated
& Mechanistically Proven
We measure hard biological endpoints to prove the hybrid effect. Our Phase 2 results demonstrated significant improvements in the Unified Parkinson's Disease Rating Scale (UPDRS) Parts 2 & 3 compared to a placebo app. Furthermore, fMRI imaging confirmed our ability to activate specific neural circuits through digital intervention.
fMRI Imaging
Visualizing changes in brain connectivity and structure.
Biomarkers
Analyzing blood and saliva for markers of inflammation (Cortisol, Cytokines).
Standardized
Clinical ScalesUsing the gold-standard metrics for each disease state (e.g., MDS-UPDRS for Parkinson's).
The Evidence, Published
Our Phase IIa results are now peer-reviewed and published in Brain Communications (Oxford University Press, 2026).
In a 3-week Phase IIa study of 41 people iving with Parkinson's using an investigational app, 90% responded, with 65% reaching a clinically meaningful improvement threshold.
Use of the investigation app was associated with a 9.7-point improvement in MDS-UPDRS total score (sum of Parts I, II and III) compared to the 1.95 point improvement in the placebo arm. fMRI confirmed what the scores showed: Hybridopa measurably strengthened motor circuit connectivity in the brain.
Join our. Clinical Trials.
Remepy is currently conducting clinical trials for Parkinson’s Disease patients. If you are interested in learning more about our clinical trials, join our newsletter today.
